基本信息
views: 221
Career Trajectory
Bio
Between 1988 and 1995, he was the recipient of three fellowships in Medical Genetics and Gynecologic Oncology. In 1995, Dr. Monk was appointed Director of Gynecologic Oncology at Texas Tech University Health Services Center and, from 1998 until 2010, was Associate Professor with Tenure of the Division of Gynecologic Oncology, Department of Obstetrics and Gynecology at the Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center and Director of Research in the Department of Obstetrics and Gynecology. Dr. Monk was then appointed Director and Professor in the Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Creighton University School of Medicine at St. Joseph’s Hospital and Medical Center in Phoenix, AZ. In 2016, he became a member of Arizona Oncology and part of the US Oncology Network and continues to practice in Phoenix. Most recently, he has been appointed the US Oncology Medical Director of Gynecologic Oncology Research. Dr. Monk is also a Professor on the Clinical Scholar Track at the University of Arizona College of Medicine – Phoenix and works at Arizona Oncology (US Oncology Network). He has been named one of Arizona’s “Top Doctors” by PHOENIX magazine 5 years in a row beginning in 2012.
Dr. Monk’s research interests include the prevention and treatment of gynecologic cancers. He was the first to report the activity of anti-vascular growth factor (VEGF) therapy in ovarian cancer and his papers in the New England Journal of Medicine led to the global approval of anti-VEGF therapy and PARP inhibitors in recurrent ovarian and cervical cancers in 2014. He was also the lead author on the pivotal trial of trabectedin in recurrent ovarian cancer as well as many other studies that have met their primary endpoints. Dr. Monk was also awarded the highly prestigious Ernst Wertheim Award for his research in cervical cancer and is on the Board of Directors for the GOG Foundation, Inc. and is the Cervical Cancer Chair for for the Gynecologic Cancer Intergroup (GCIG). He is past President of the Western Association of Gynecologic Oncologists (WAGO) and current co-director for the GOG Research Consortium (GOG-Partners).
Dr. Monk’s research interests include the prevention and treatment of gynecologic cancers. He was the first to report the activity of anti-vascular growth factor (VEGF) therapy in ovarian cancer and his papers in the New England Journal of Medicine led to the global approval of anti-VEGF therapy and PARP inhibitors in recurrent ovarian and cervical cancers in 2014. He was also the lead author on the pivotal trial of trabectedin in recurrent ovarian cancer as well as many other studies that have met their primary endpoints. Dr. Monk was also awarded the highly prestigious Ernst Wertheim Award for his research in cervical cancer and is on the Board of Directors for the GOG Foundation, Inc. and is the Cervical Cancer Chair for for the Gynecologic Cancer Intergroup (GCIG). He is past President of the Western Association of Gynecologic Oncologists (WAGO) and current co-director for the GOG Research Consortium (GOG-Partners).
Research Interests
Papers共 797 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Nicoletta Colombo, Domenica Lorusso,Bradley J Monk,Brian Slomovitz,Kosei Hasegawa,Angélica Nogueira-Rodrigues,Melissa Zale,Chinyere E Okpara,Gianmaria Barresi,Jodi McKenzie,Vicky Makker
The oncologistno. 1 (2024): 25-35
Whitney S Graybill, Beatriz Pardo Búrdalo, David M O'Malley,Ignace Vergote,Bradley J Monk, Annika Auranen,Larry J Copeland,Roberto Sabbatini,Thomas J Herzog, Philippe Follana,Bhavana Pothuri, Elena Ioana Braicu,
International journal of gynecological cancer : official journal of the International Gynecological Cancer Societyno. 7 (2024): 1041-1050
Mansoor R Mirza,Antonio González-Martín,Whitney S Graybill, David M O'Malley,Lydia Gaba, Oi Wah Stephanie Yap,Eva M Guerra,Peter G Rose,Jean-François Baurain,Sharad A Ghamande,Hannelore Denys,Emily Prendergast,
Future oncology (London, England)no. 13 (2024): 799-809
Christof Vulsteke,Setsuko K. Chambers, Maria Jesús Rubio Pérez,John K. Chan, Nicoline Raaschou-Jensen, Ying Zhuo, Domenica Lorusso,Thomas J. Herzog,Thibault de la Motte Rouge, Jessica A. Thomes Pepin, Elena Ioana Braicu,Lee-may Chen,
European Journal of Cancerpp.114157, (2024)
Bradley J Monk, Nicoletta Colombo,Krishnansu S Tewari,Cumhur Tekin,Stephen M Keefe, Domenica Lorusso
Journal of clinical oncology : official journal of the American Society of Clinical Oncologyno. 13 (2024): 1596-1598
The Lancet Oncologyno. 3 (2024): e96
Ritu Salani,Mary McCormack,Yong-Man Kim,Sharad Ghamande, Shaundra L Hall,Domenica Lorusso, Lisa Barraclough,Lucy Gilbert, Adrian Guzman Ramirez,Chien-Hsing Lu,Renaud Sabatier, Nicoletta Colombo,
International journal of gynecological cancer : official journal of the International Gynecological Cancer Societypp.ijgc-2024, (2024)
European Journal of Cancer (2024): 114024-114024
JAMA oncologyno. 2 (2024): 185-192
Neil S Horowitz, Wei Deng, Ivy Peterson,Robert S Mannel,Spencer Thompson, Elizabeth Lokich,Tashanna Myers,Parvis Hanjani, David M O'Malley,Ki Young Chung,David S Miller,Frederick R Ueland,
Journal of clinical oncology : official journal of the American Society of Clinical Oncologyno. 16 (2024): 1914-1921
Load More
Author Statistics
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn